European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Transgene SA, Illkirch-Graffenstaden, France

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Transgene SA

Identification

Sirul
Siren 317540581
Stockp
TNG.PA
Stockp
TRGNF
Siret
Siret 31754058100087
Lei
969500PDJW8N0FSGGK69

Address

400 Gonthier d'Andernach, 67400 Illkirch-Graffenstaden, France
Strasbourg, France

Corporate purpose

72.11
Research and experimental development on biotechnology

Research genetic engineering, development, production, marketing of medicines

Financials

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network
CSV export

Investigative Journalism

Uncover International Corporate Connections with our Free Investigative-Account

Annual report

Publications

28 Aug 2025
Chair of the board: Alessandro Riva · Deputy Director-General: Christophe Ancel · Director (9) · Auditor: Grant Thornton, KPMG SA · Capital: €39.8M · Corporate Purpose
28 Aug 2025
Capital: €39.7M · Corporate Purpose
28 Jul 2025 via Sogec 2 N.V. also 05/07/2024, 22/06/2023
Shareholder: Sogec 2 N.V
5 Jun 2025
Consolidated Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024 · Earnings statement for 31/12/2023
12 Feb 2025
Patent: Immunotherapeutic Vaccine and Antibody Combination Therapy
31 Dec 2024
Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024
19 Sept 2024
Capital: €66.1M · Corporate Purpose
19 Jun 2024
Director-General: Alessandro Riva · Chair of the board: Alessandro Riva · Dep.DG: Christophe Ancel · Director (9) · Auditor: Grant Thornton, KPMG SA · Capital: €50.7M · Corporate Purpose
31 Dec 2023
Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023
12 Oct 2023
Director-General: Alessandro Riva · Chair of the board: Alessandro Riva · Deputy Director-General: Christophe Ancel · Director (8) · Auditor (3 companies) · Capital: €50.4M · Corporate Purpose
18 Aug 2023
Patent: Chimeric Poxviruses
30 Jun 2023
Patent: Fusion Protein Comprising a Surfactant-Protein-D and a Member of the TNFSF
14 Jun 2023
Director-General: Alessandro Riva · Chair of the board: Alessandro Riva · Deputy Director-General: Christophe Ancel · Director (9) · Auditor (3 companies) · Capital: €50.4M · Corporate Purpose
9 Jun 2023
Patent: Recombinant Virus Expressing Interleukin-12
31 Dec 2022
Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022
8 Oct 2022
No longer DG: Jean-F. Carmier · Director (18) · No longer Director (9) · No longer Auditor (3) · DG (3) · Auditor (2) · Director: Tsgh SAS · No longer Director: Biomerieux Pierre Fabre SA · No longer …
Year 2022 in Epobase
4 European patent filings: Novel Combinations of Antibodies and Uses Thereof …
9 Aug 2022
Chair of the board: Alessandro Riva · Deputy Director-General: Christophe Ancel · Director (7) · Director-General (1) · Director: TSGH (SAS) · Auditor (3 companies) · Capital: €50.1M
21 Jul 2022
Director (4) · No longer Director (3) · Director-General (1) · Auditor: Kpmg SA · No longer Auditor (2 companies)
5 Jun 2022
Capital: €49.8M
7 May 2022
Reg­is­tra­tion: 07/05/2022 · Address · Legal form · Name: TRANSGENE · Segment clas­si­fi­ca­tion
31 Dec 2021
Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021
24 Nov 2021
Patent: Oncolytic Viruses and Therapeutic Molecules
28 Sept 2021
Capital: €48.9M
13 Jul 2021
Patent: Treatment of Immune Depression
1 Jul 2021 in Hor
EU funding: Building a reproducible single-cell experimental workflow to capture tumour cell persistence
28 Mar 2021
Deputy Director-General: Christophe Ancel · Director (10) · Chair of the board (1) · Director-General (1) · Director: TSGH (SAS) · Auditor (4 companies)
22 Mar 2021
Director-General (1) · Director (2)
2 Jan 2021
Capital: €41.9M
31 Dec 2020
Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
22 Dec 2020
Patent: Process for Designing a Recombinant Poxvirus for a Therapeutic Vaccine
1 Oct 2020
Director-General: Christophe Ancel, Philippe Archinard · Director (8) · Director: Tsgh SAS · Auditor (4 companies)
21 Sept 2020
Patent: Combination of a Poxvirus Encoding HPV Polypeptides and IL-2 with an Anti-PD-L1 Antibody
15 Sept 2020
Word figurative mark: “transgene“
2 Sept 2020
Patent: Combination of Oncolytic Virus with Immune Checkpoint Modulators
26 Jun 2020
Capital: €83.8M
31 Dec 2019
Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
Year 2019 in Epobase
10 European patent filings: M2-Defective Poxvirus …
1 Dec 2019 in Hor
EU funding: Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies
10 Sept 2019
Capital: €83.3M
28 Jul 2019
Chair of the board: Philippe Archinard · Deputy Director-General: Christophe Ancel · Director (8) · Director: TSGH (SAS) · Auditor (4 companies)
18 Jun 2019
Capital: €62.4M
5 May 2019 via Elsalys Biotech SA
No longer Director: Elsalys Biotech SA
18 Apr 2019 via Elsalys Biotech SA
No longer Director: Elsalys Biotech SA
31 Dec 2018
Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
Year 2018 in Epobase
4 European patent filings: Mycobacterial Antigen Vaccine …
12 Nov 2018 in Hor
EU funding: Interdisciplinary training network for advancing Organ-on-a-chip technology in Europe
20 Jul 2018
Capital: €62.3M
6 Mar 2018 via Elsalys Biotech SA
Director: Elsalys Biotech SA
16 Feb 2018
Capital: €62.1M
31 Dec 2017
Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
Year 2017 in Epobase
5 European patent filings: Cowpox-Based Oncolytic Vectors …
24 Oct 2017
Chair of the board: Philippe Archinard · Deputy Director-General: Christophe Ancel · Director (9) · Director: TSGH (SAS) · Auditor (4 companies)
8 Jun 2017
Name: TRANSGENE
7 Mar 2017
Capital: €56.4M
31 Dec 2016
Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
Year 2016 in Epobase
6 European patent filings: Immortalized Avian Cell Lines …
12 Aug 2016
Chair of the board: Philippe Archinard · Deputy Director-General: Christophe Ancel · Director (9) · Director: TSGH (SAS) · Auditor (4 companies) · Capital: €38.5M
Year 2016 in Dpmap
11 patent filings: Stabile Flüssige Vaccinia Virus Zusammensetzungen …
7 Apr 2016
Capital: €88.2M
8 Mar 2016 via Kcas bio SAS
No longer Director: Platine Pharma Services SAS
31 Dec 2015
Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015
Year 2015 in Epobase
6 European patent filings: Biomarker for Monitoring Patients …
Year 2015 in Dpmap
6 patent filings: Onkolytische Poxvirus-Vektoren …
15 May 2015 via Elsalys Biotech SA
No longer President: Elsalys Biotech SA
10 May 2015
Wordmark: “FUSOKINE“
11 Feb 2015
Capital: €88.2M
1 Jan 2015 in Hor
EU funding: TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development
31 Dec 2014
Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014
10 Oct 2014 via Kcas bio SAS
Director: Platine Pharma Services SAS
17 Jun 2014
Capital: €88M
24 Apr 2014 via Elsalys Biotech SA
President: Elsalys Biotech SA
9 Apr 2014
Director-General: Philippe Archinard · Chair: Philippe Archinard · Dep.DG: Christophe Ancel · Director (9) · Auditor (2) · Director: TSGH (SAS) · Auditor: Auditex, Societe Barbier Frinault et Autres
9 Apr 2014
Capital: €72.9M
Year 2014 in Dpmap
6 patent filings: Impfstoff mit Einem Mykobakteriellen Antigen …
8 Jan 2014
Patent: Biomarker for Monitoring Patients
31 Dec 2013
Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013
8 Nov 2013
Patent: Modulation of Monocytes, or Precursors Thereof, Differentiation
23 Oct 2013 via Kcas bio SAS
Director: Platine Pharma Services SAS
20 Sept 2013
Chair of the board: Philippe Archinard · Director (9) · Director-General (1) · Auditor (2) · Director: TSGH (SASh) · Auditor: Auditex, Societe Barbier Frinault et Autres
10 Jul 2013
Patent: Mycobacterium Resuscitation Promoting Factor for USE AS Adjuvant
19 May 2013
Capital: €72.9M
17 Apr 2013
Patent: Vectors for Multiple Gene Expression
31 Dec 2012
Balance sheet for 31/12/2012 · Earnings statement for 31/12/2012
Year 2012 in Epobase
5 European patent filings: Modulation of Macrophage Activation …
11 Oct 2012
Change in the name
28 Sept 2012 as Trangene SA
Patent: Immunotherapy Composition and Regimen for Treating Hepatitis C Virus Infection
24 Jun 2012
Capital: €72.5M
8 Apr 2012
Capital: €72.5M
1 Jan 2012 in Fts
EU funding (€521,548): Toward Enhancing Activities of European Institutions in the Fduscc-IM Cancer Research Joint Institute in China
31 Dec 2011
Balance sheet for 31/12/2011 · Earnings statement for 31/12/2011
Year 2011 in Epobase
5 European patent filings: Papillomavirus E2 Polypeptide Used for Vaccination …
25 May 2011
Capital: €72.5M
31 Dec 2010
Balance sheet for 31/12/2010 · Earnings statement for 31/12/2010
Year 2010 in Dpmap
5 patent filings: Antikörper Gegen CSF-1 R …
10 Oct 2010
Chair of the board: Philippe Archinard · Director (9) · Auditor (3) · Deputy Director-General (1) · Director: TSGH (SAS) · Auditor: Societe Barbier Frinault et Autres · Capital: €72.5M
10 Oct 2010
Chair of the board: Philippe Archinard · Director (9) · Deputy Director-General (1) · Auditor (2) · Director: TSGH (SAS) · Auditor: Auditex, Societe Barbier Frinault et Autres
Year 2010 in Epobase
7 European patent filings: Polypeptide Having an Improved Cytosine Deaminase Activity …
13 Jul 2010
Capital: €50.7M
23 Apr 2010
Capital: €50.7M
31 Dec 2009
Balance sheet for 31/12/2009 · Earnings statement for 31/12/2009
18 Dec 2009
Patent: A Method and a System for Automatically Processing Multiple Measurements of Biological Quantifiable Parameters
Year 2009 in Dpmap
4 patent filings: Antikörper Gegen CSF-1 R …
27 May 2009
Patent: Biomarker for Selecting Patients and Related Methods
17 Mar 2009
Capital: €50.6M
17 Mar 2009
Capital: €50.6M
21 Jan 2009
Patent: Kit of Parts Designed for Implementing an Antitumoral or Antiviral Treatment in a Mammal
31 Dec 2008
Balance sheet for 31/12/2008 · Earnings statement for 31/12/2008
16 Dec 2008
Address
Year 2008 in Epobase
4 European patent filings: Poxvirus with Targeted Infection Specificity …
15 Oct 2008
Patent: Aviäre Telomerase Reverse Transkriptase
31 Aug 2008
Director (4) · No longer Director (1) · Capital: €50.6M
7 Aug 2008
Patent: Zur Impfung Verwendetes Papillomavirus-E2-Polypeptid
20 Apr 2008
Capital: €50.6M
1 Jan 2008
Segment clas­si­fi­ca­tion
1 Jan 2008 in Fts
EU funding: O-PTM-Biomarkers
31 Dec 2007
Balance sheet for 31/12/2007 · Earnings statement for 31/12/2007
Year 2007 in Epobase
8 European patent filings: Means and Method for Raising Improved Immune Response …
31 Dec 2006
Balance sheet for 31/12/2006 · Earnings statement for 31/12/2006
Year 2006 in Epobase
5 European patent filings: MUC-1 Derived Peptides …
Year 2005 in Epobase
8 European patent filings: Mutant Having Uracil Phosphoribosyl Transferase Activity …
1 Jan 1981
Address · Legal form
1 Jan 1979
Name: TRANSGENE SA
There are no publications matching your search.

Mentions

18 Feb 2025 in Psc
Companies House - Persons with Significant Control
1 Jul 2024 in Rne
Reg­is­tra­tion: 16/12/2008 · Director-General: Alessandro Riva · Chair: Alessandro Riva · Dep.DG: Christophe Ancel · Director (8) · Capital: €50.7M · Segment clas­si­fi­ca­tion · Corporate Purpose
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Transgene SA, Illkirch-Graffenstaden, France" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.